Prevalence of cardiovascular comorbidities and utilization of evidence-based treatment strategies among statin users in a Medicare and commercial health plan^*

References

• Carroll MD, Lacher DA, Sorlie PD, et al. Trends in serum lipids and lipoproteins of adults, 1960-2002. JAMA 2005;294:1773-81
   PubMed Web of Science ®Google Scholar
• Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics–2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007;115:e69-171
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78
   PubMed Web of Science ®Google Scholar
• Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96
   PubMed Web of Science ®Google Scholar
• Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-93
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22
   PubMed Web of Science ®Google Scholar
• LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004;291:1071-80
   PubMed Web of Science ®Google Scholar
• Cannon CP, Braunwald MD, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504
   PubMed Web of Science ®Google Scholar
• Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58
   PubMed Web of Science ®Google Scholar
• Thavendiranathan P, Bagai A, Brookhart MA, et al. Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Arch Intern Med 2006;166:2307-13
   PubMed Web of Science ®Google Scholar
• Messerli FH, Pinto L, Tang SSK, et al. Impact of systemic hypertension on the cardiovascular benefits of statin therapy – a meta-analysis. Am J Cardiol 2008;101:319-25
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39
   PubMed Web of Science ®Google Scholar
• Kannel WB. Fifty years of Framingham Study contributions to understanding hypertension. J Hum Hypertens 2000;14:83-90
   PubMed Web of Science ®Google Scholar
• Johnson ML, Pietz K, Battleman DS, et al. Prevalence of comorbid hypertension and dyslipidemia and associated cardiovascular disease. Am J Manag Care 2004;10:926-32
   PubMed Web of Science ®Google Scholar
• Selby JV, Peng T, Karter AJ, et al. High rates of co-occurrence of hypertension, elevated low-density lipoprotein cholesterol, and diabetes mellitus in a large managed care population. Am J Manag Care 2004;10:163-70
   PubMed Web of Science ®Google Scholar
• Thomas F, Bean K, Guize L, et al. Combined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young (< 55 years) men and women. Eur Heart J 2002;23:528-35
   PubMed Web of Science ®Google Scholar
• Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992;152:56-64
   PubMed Web of Science ®Google Scholar
• Foody JM, Joyce AT, Rudolph AE, et al. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States. Clin Ther 2008;30:195-205
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143-421
   Google Scholar
• Adams RJ, Albers G, Alberts MJ, et al. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 2008;39:1647-52
   PubMed Web of Science ®Google Scholar
• Kidney Disease Outcomes Quality Initiative (K/DOQI) Group. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis 2003;41:I-IV, S1-91
   PubMedGoogle Scholar
• Dutro MP, Gerthoffer TD, Peterson ED, et al. Treatment of hypertension and dyslipidemia or their combination among US managed-care patients. J Clin Hypertens (Greenwich) 2007;9:684-91
   PubMedGoogle Scholar
• Dutro M, Koo YH, Koren AT, et al. Heart failure and managed care: Clinical characteristics and quality of drug therapy. Drug Benefit Trends 2005;17:571-80
   Google Scholar
• Raymond CB, Morgan SG, Katz A, et al. A population-based analysis of statin utilization in British Columbia. Clin Ther 2007;29:2107-19
   PubMed Web of Science ®Google Scholar
• Farahani P, Levine M, Gaebel K, et al. Exploring patient demographic and clinical characteristics associated with lipid-lowering pharmacotherapy use in primary care. Clin Invest Med 2007;30:E63-9
   PubMed Web of Science ®Google Scholar
• Kannel WB. Hypertensive risk assessment: cardiovascular risk factors and hypertension. J Clin Hypertens (Greenwich) 2004;6:393-9
   PubMedGoogle Scholar
• O'Meara JG, Kardia SL, Armon JJ, et al. Ethnic and sex differences in the prevalence, treatment, and control of dyslipidemia among hypertensive adults in the GENOA study. Arch Intern Med 2004;164:1313-18
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006;295:180-9
   PubMed Web of Science ®Google Scholar
• Wong ND, Lopez V, Tang S, et al. Prevalence, treatment, and control of combined hypertension and hypercholesterolemia in the United States. Am J Cardiol 2006;98:204-8
   PubMed Web of Science ®Google Scholar
• Xuan J, Duong PT, Russo PA, et al. The economic burden of congestive heart failure in a managed care population. Am J Manag Care 2000;6:693-700
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Clinical Practice Recommendations 2007. Diabetes Care 2007;30 (Suppl 1)
   Web of Science ®Google Scholar
• Smith SC Jr., Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006;113:2363-72
   PubMed Web of Science ®Google Scholar
• Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005;112:e154-235
   PubMed Web of Science ®Google Scholar
• Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005;294:2437-45
   PubMed Web of Science ®Google Scholar
• Candrilli SD, Kuznik A, Rudolph AE. The prevalence and overlap of selected cardiovascular co-morbidities among US adults with dyslipidemia, by lipid-lowering medication use status. Poster presented at the American College of Pharmacy annual meeting, October 13-17, 2007, Denver, Colorado
   Google Scholar
• Penning-van Beest FJ, Termorshuizen F, Goettsch WG, et al. Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study. Eur Heart J 2007;28:154-9
   PubMed Web of Science ®Google Scholar
• Bouchard MH, Dragomir A, Blais L, et al. Impact of adherence to statins on coronary artery disease in primary prevention. Br J Clin Pharmacol 2007;63:698-708
   PubMed Web of Science ®Google Scholar
• Thiebaud P, Patel BV, Nichol MB, et al. The effect of switching on compliance and persistence: the case of statin treatment. Am J Manag Care 2005;11:670-4
   PubMed Web of Science ®Google Scholar
• Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics – 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008;117:e25-146
   PubMed Web of Science ®Google Scholar